trending Market Intelligence /marketintelligence/en/news-insights/trending/ivAYvHZ3rHy-s8jkEi_dTw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca-Daiichi Sankyo breast cancer drug gets US FDA nod 3 months early

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AstraZeneca-Daiichi Sankyo breast cancer drug gets US FDA nod 3 months early

The U.S. Food and Drug Administration granted accelerated approval to AstraZeneca PLC and Daiichi Sankyo Co. Ltd.'s Enhertu for the treatment of certain breast cancer patients who are ineligible for surgery.

Enhertu's application received priority review in October, and has now been approved three months ahead of schedule. The FDA originally planned to respond to the application by the second quarter of 2020.

The drug regulator approved Enhertu, or trastuzumab deruxtecan, to treat patients with human epidermal growth factor receptor 2-positive breast cancer that has spread across the body or has metastasized after receiving two or more therapies. The FDA said the approval is based on a phase 2 clinical trial called Destiny-Breast01, which showed positive results in patients with this type of breast cancer.

AstraZeneca and Daiichi Sankyo are developing the cancer treatment through a partnership agreement. British pharmaceutical giant AstraZeneca paid Daiichi Sankyo $1.35 billion upfront to share costs and profits for the development and commercialization of Enhertu worldwide, excluding Japan. Tokyo-based Daiichi Sankyo is solely responsible for the manufacturing and supply of Enhertu.

The drug previously received breakthrough therapy and fast track designations from the FDA for treating patients with HER2-positive breast cancer that is locally advanced or has spread to other organs.

SNL Image